Illumina, Inc. (NASDAQ:ILMN) Short Interest Up 10.2% in November

Illumina, Inc. (NASDAQ:ILMN) was the target of a large growth in short interest in November. As of November 30th, there was short interest totalling 7,210,000 shares, a growth of 10.2% from the November 15th total of 6,540,000 shares. Based on an average daily volume of 1,900,000 shares, the short-interest ratio is presently 3.8 days.

Illumina Stock Up 0.4 %

Shares of NASDAQ:ILMN opened at $144.40 on Tuesday. The firm has a market cap of $22.90 billion, a PE ratio of -14.50 and a beta of 1.11. The company has a fifty day simple moving average of $144.35 and a 200 day simple moving average of $128.93. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina has a 12-month low of $100.08 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.33 EPS. On average, equities research analysts anticipate that Illumina will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. UBS Group increased their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. Barclays lifted their target price on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Leerink Partners increased their price target on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, Canaccord Genuity Group boosted their price objective on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research note on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Illumina has an average rating of “Moderate Buy” and an average target price of $165.95.

Institutional Trading of Illumina

Several institutional investors and hedge funds have recently bought and sold shares of ILMN. Industrial Alliance Investment Management Inc. acquired a new position in shares of Illumina in the 2nd quarter worth approximately $34,000. TD Private Client Wealth LLC lifted its stake in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its holdings in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares during the period. Private Trust Co. NA increased its stake in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares during the last quarter. Finally, Focused Wealth Management Inc acquired a new stake in shares of Illumina during the third quarter worth $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.